johnson-and-johnson pharma healthcare lobbying talc opioids drug-pricing
related: PhRMA Pfizer UnitedHealth Group - Optum
Who They Are
Johnson & Johnson (J&J). One of the largest pharmaceutical and medical device companies in the world with $85 billion in annual revenue (2024). J&J operates across three segments: pharmaceuticals (Janssen), medical devices, and consumer health (spun off as Kenvue in 2023). J&J PAC contributes $1.5-2 million per cycle and the company spends $8-10 million annually on lobbying.
J&J has faced extraordinary legal liability: $8.9 billion in proposed settlements for its talc/asbestos cancer cases (affecting 60,000+ plaintiffs) and participation in the $26 billion national opioid settlement. The company’s legal strategy — including a controversial “Texas Two-Step” bankruptcy maneuver to limit talc liability — has drawn congressional scrutiny and judicial rejection.
What They Want
Drug pricing: J&J opposes Medicare drug price negotiation and lobbied intensively against the Inflation Reduction Act’s negotiation provisions. Patent protection: J&J seeks to maximize patent exclusivity periods and opposes legislation enabling faster generic/biosimilar entry. Liability limitation: J&J lobbies for tort reform and bankruptcy law changes that would limit its exposure in mass tort litigation. FDA regulatory streamlining: faster drug approval pathways that reduce time-to-market.
Who They Fund
Bipartisan distribution targeting Finance Committee (Medicare drug pricing), Judiciary Committee (patent law, bankruptcy reform), and HELP Committee (FDA regulation) members.
What They’ve Gotten
Medicare Negotiation Limited (Pre-2022): For decades, J&J and PhRMA successfully prevented Medicare from negotiating drug prices — a prohibition worth hundreds of billions to the pharmaceutical industry. The IRA’s 2022 negotiation authority covers only 10 drugs initially, preserving the majority of the industry’s pricing power.
Patent Evergreening Protected: The pharmaceutical patent system allows J&J and peers to extend market exclusivity through secondary patents, product modifications, and regulatory strategies. Congressional legislation to limit patent evergreening has repeatedly stalled.
Money
J&J’s single drug Stelara generated $21.4 billion in revenue in 2023. Medicare negotiation could reduce prices on drugs like Stelara by 25-60%. J&J’s $10 million annual lobbying spend protects billions in drug revenue. The lobbying ROI is measured in thousands of percent.
Sources
- OpenSecrets: Johnson & Johnson organizational profile (Tier 1)
- OpenSecrets: J&J lobbying expenditures (Tier 1)
- Reuters: J&J talc settlement and bankruptcy strategy (Tier 2)
- Ballotpedia: Johnson & Johnson political spending (Tier 3)
content-readiness:: ready